will compounded tirzepatide be discontinued What is the latest update on the ban FDA ban on compounded tirzepatide:

Patients should be counseled about the importance of adherence to the weekly dosing schedule

Taking SEMBOLIC 14 TABLET on an Empty Stomach Take the tablet on an empty stomach, at least 30 minutes before consuming food, beverages, or other oral medications

It is not FDA-approved for weight loss and is typically sold outside standard prescription channels as a compounded or research product

Competitive pricing for large-scale orders

Semaglutide is an FDA-approved GLP-1 receptor agonist intended for adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher accompanied by a weight-related health condition

Heres a common Wegovy dosing schedule: Month 1 (Weeks 14): 0.25 mg per week (starting dose) Month 2 (Weeks 58): 0.5 mg Month 3 (Weeks 912): 1.0 mg Month 4 (Weeks 1316+): 1.7 mg Month 5 and beyond: 2.4 mg per week Doses higher than 2.4 mg weekly are not approved and have not been studied for safety or efficacy